rulonilimab + F007

F520 + F007 is a combination therapy developed by Shandong New Time Pharmaceutical Co., Ltd. for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The combination consists of F520 (rulonilimab), a recombinant humanized monoclonal antibody that targets the programmed cell death-1 (PD-1) receptor, and F007, a biosimilar of the anti-CD20 antibody rituximab. Rulonilimab acts as an immune checkpoint inhibitor by blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby stimulating T lymphocyte activity against tumor cells. F007 targets the CD20 antigen on the surface of B-cells, inducing cell death through mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This dual-action approach aims to enhance the immune response while directly depleting malignant B-cells, and it is currently being evaluated in Phase II clinical trials.

Other names

rulonilimab + rituximab biosimilar